Astegolimab for Long-Term COPD Safety
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- Age
- 40 – 90
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 2,000 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
This trial is looking for people with chronic obstructive pulmonary disease (COPD) who have completed a 52-week treatment period in a related study. Participants will help researchers understand the long-term safety and effectiveness of astegolimab.
You may be able to join if
- I have completed a 52-week treatment period in a related study.
You may not be able to join if
- I withdrew my consent from the previous study.
- I discontinued the study drug permanently in the previous study.
- I missed scheduled visits during the previous study.
- I was diagnosed with asthma since enrolling in the previous study.
- I have a new clinically significant lung disease other than COPD.
- I have new unstable heart disease or heart failure since enrolling in the previous study.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Loading trial locations…
Reference Study ID Number: GB43374 https://forpatients.roche.com/ No attachments to email below.
888-662-6728
global-roche-genentech-trials@gene.com
CONTACT
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT